# Hederacoside C

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/hederacoside-c
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** Hedera helix saponin C, Ivy saponin C, English ivy saponin C, Oleanane-type glycoside C, Kalopanax saponin C, Triterpenoid saponin C from Hedera helix

## Overview

Hederacoside C is a triterpenoid saponin derived primarily from Hedera helix (common ivy) leaves, where it functions as a major bioactive glycoside. It exerts its effects chiefly through inhibition of [acetylcholine](/ingredients/condition/cognitive)sterase and modulation of inflammatory signaling pathways, placing it under active preclinical investigation for cognitive and [anti-inflammatory](/ingredients/condition/inflammation) applications.

## Health Benefits

• [Anti-inflammatory](/ingredients/condition/inflammation) activity demonstrated in preclinical studies (evidence quality: preliminary) • [Acetylcholine](/ingredients/condition/cognitive)sterase inhibition with IC₅₀ = 31.3 µM, suggesting potential cognitive support (evidence quality: preliminary) • Antimutagenic effects reducing aflatoxin B1-induced mutagenicity by 21-67% at 0.5-5 µg doses in bacterial cultures (evidence quality: preliminary) • Component of Hedera helix extracts used for respiratory conditions like bronchitis (evidence quality: traditional use only) • Potential bioavailability enhancer for other compounds in oral formulations (evidence quality: preliminary)

## Mechanism of Action

Hederacoside C inhibits the enzyme [acetylcholine](/ingredients/condition/cognitive)sterase with an IC₅₀ of 31.3 µM, reducing the hydrolysis of acetylcholine at synaptic junctions and thereby prolonging cholinergic neurotransmission. It also suppresses pro-[inflammatory](/ingredients/condition/inflammation) mediator production, likely through downregulation of NF-κB signaling and inhibition of cyclooxygenase-related pathways, though the precise upstream receptor targets remain under investigation. Its antimutagenic activity appears linked to the inhibition of cytochrome P450-mediated bioactivation of aflatoxin B1 into its reactive epoxide form, reducing DNA adduct formation.

## Clinical Summary

The evidence base for hederacoside C consists entirely of in vitro and animal-model studies, with no published randomized controlled trials isolating this compound in human subjects. Antimutagenic activity was quantified in Salmonella-based Ames test assays, where hederacoside C reduced aflatoxin B1-induced mutagenicity by 21–67% depending on concentration. [Acetylcholine](/ingredients/condition/cognitive)sterase inhibition was demonstrated in enzyme-based biochemical assays with an IC₅₀ of 31.3 µM, a value considered moderate compared to pharmaceutical inhibitors such as donepezil (IC₅₀ ~0.023 µM). [Anti-inflammatory](/ingredients/condition/inflammation) effects have been observed in cell-based models, but translation to clinical outcomes in humans has not been established, and all findings should be considered preliminary.

## Nutritional Profile

Hederacoside C is a purified triterpenoid saponin compound (not a whole food or nutritional ingredient), therefore it does not possess a conventional macronutrient or micronutrient profile. Structurally, it is a bidesmosidic oleanolic acid glycoside with molecular formula C₅₉H₉₆O₂₆ and molecular weight of approximately 1221.4 g/mol. It consists of an oleanolic acid aglycone core esterified with a complex sugar chain including glucose, rhamnose, arabinose, and apiose residues. As a saponin, it contains no dietary protein, fat, or fiber in the nutritional sense. Bioactive compound concentration in dried Hedera helix (ivy) leaf extract typically ranges from 0.5–5% total hederasaponin content, with hederacoside C representing a significant fraction alongside hederacoside B and α-hederin. Oral bioavailability is considered low for intact saponin form due to poor gastrointestinal absorption; metabolic conversion to the active monodesmosidic form α-hederin via intestinal hydrolysis of the terminal sugar is believed to be responsible for primary biological activity in vivo. No vitamins, dietary minerals, or fiber content are inherently associated with this isolated compound. Standardized ivy leaf dry extracts (e.g., EA 575) are typically normalized to 5–7.5 mg hederacoside C per dose in clinical phytomedicine formulations.

## Dosage & Preparation

No clinically studied dosage ranges for Hederacoside C in humans are available. The compound has been used in research formulations with DMSO master liquids diluted in PEG300, Tween 80, or corn oil, but human dosing data is not established. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Hederacoside C has not been evaluated in dedicated human safety or toxicology trials, making a complete adverse effect profile unavailable. As a constituent of Hedera helix preparations, it may contribute to reported side effects of ivy leaf extracts including nausea, vomiting, and allergic skin reactions, particularly in individuals with sensitivities to Araliaceae family plants. Its [acetylcholine](/ingredients/condition/cognitive)sterase-inhibiting activity raises a theoretical interaction risk with cholinergic drugs such as donepezil, rivastigmine, or anticholinergic medications, potentially altering their pharmacodynamic effects. Use during pregnancy and lactation is not recommended due to the absence of safety data, and individuals with liver conditions should exercise caution given limited metabolic characterization.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Hederacoside C are available in the current research. All evidence comes from preclinical studies including [acetylcholine](/ingredients/condition/cognitive)sterase inhibition assays and antimutagenic testing in S. typhimurium cultures, with no PubMed PMIDs identified.

## Historical & Cultural Context

Hederacoside C is an active component in Hedera helix leaf extracts traditionally used in European herbalism for respiratory disorders such as acute respiratory infections and bronchitis. Specific historical context and duration of use are not documented in available sources.

## Synergistic Combinations

Other saponins, respiratory botanicals, [acetylcholine](/ingredients/condition/cognitive)sterase inhibitors, [anti-inflammatory](/ingredients/condition/inflammation) compounds, bioavailability enhancers

## Frequently Asked Questions

### What is hederacoside C and where does it come from?

Hederacoside C is a triterpenoid saponin glycoside found predominantly in the leaves of Hedera helix, commonly known as English ivy. It belongs to the oleanane-type saponin class and is one of the primary bioactive constituents extracted from ivy leaf preparations used in European herbal medicine, particularly for respiratory applications.

### How does hederacoside C affect the brain and cognition?

Hederacoside C inhibits acetylcholinesterase, the enzyme responsible for breaking down the neurotransmitter acetylcholine in synaptic clefts, with a measured IC₅₀ of 31.3 µM in biochemical assays. By slowing acetylcholine degradation, it theoretically prolongs cholinergic signaling, a mechanism shared by Alzheimer's drugs like donepezil, though hederacoside C is substantially less potent and has not been tested in human cognitive trials.

### Can hederacoside C reduce inflammation?

Preclinical in vitro studies have demonstrated that hederacoside C exhibits anti-inflammatory activity, likely through suppression of NF-κB-mediated inflammatory signaling and reduction of pro-inflammatory cytokine production. However, these findings come exclusively from cell-based models, and no human clinical trials have confirmed whether these effects translate to meaningful anti-inflammatory outcomes in living subjects.

### What does the research say about hederacoside C and cancer or mutagens?

Ames test studies using Salmonella typhimurium strains showed that hederacoside C reduced aflatoxin B1-induced mutagenicity by 21–67%, depending on the tested concentration, suggesting antimutagenic potential. This effect is thought to occur by interfering with the cytochrome P450-mediated conversion of aflatoxin B1 into its DNA-reactive 8,9-epoxide form. These are preliminary findings from bacterial mutagenicity assays, not human cancer studies, and should not be interpreted as evidence of anticancer efficacy.

### Are there any drug interactions or safety concerns with hederacoside C?

Because hederacoside C inhibits acetylcholinesterase, it carries a theoretical pharmacodynamic interaction risk with both cholinergic drugs (e.g., donepezil, rivastigmine) and anticholinergic medications (e.g., scopolamine, oxybutynin), potentially amplifying or antagonizing their effects. No human pharmacokinetic or interaction studies have been conducted on isolated hederacoside C, and its safety in pregnancy, lactation, or hepatic impairment is unknown, warranting avoidance in these populations until data are available.

### What food sources contain hederacoside C?

Hederacoside C is naturally found in Hedera helix (common ivy), where it serves as a major bioactive compound. While ivy is not typically consumed as food, it has been used in traditional herbal preparations and some botanical extracts. The concentration of hederacoside C in plant material can vary significantly depending on growing conditions, harvest timing, and plant part used.

### How strong is the current research evidence for hederacoside C?

Current research on hederacoside C is classified as preliminary, with most studies conducted in laboratory or preclinical settings rather than human clinical trials. Available evidence includes acetylcholinesterase inhibition data, antimutagenic effects in bacterial cultures, and anti-inflammatory activity in cell-based models. To establish hederacoside C's effectiveness and safety in humans, additional clinical research is needed.

### Who might benefit most from hederacoside C supplementation?

Based on preclinical research, hederacoside C may be of interest to individuals seeking cognitive support due to its acetylcholinesterase inhibitory activity, and those looking for anti-inflammatory support. However, because clinical evidence in humans is lacking, supplementation should be considered experimental and discussed with a healthcare provider before use. People with existing liver conditions or taking medications should exercise particular caution given the preliminary nature of safety data.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*